(Registrieren)

euro adhoc: Intercell AG / Joint Ventures/Cooperation/Collaboration / Intercell update on technology partnerships: Intercell outlicenses Group B Streptococcus vaccine

Geschrieben am 19-12-2008


--------------------------------------------------------------------------------
Disclosure announcement transmitted by euro adhoc. The issuer is responsible
for the content of this announcement.
--------------------------------------------------------------------------------


Research & Development

19.12.2008

» Group B Streptococcus vaccine program licensed to Novartis -
Intellectual property cross license agreement will allow Novartis
to focus on vaccines and Intercell on therapeutic antibodies in
this indication » Extension of collaboration with Sanofi Pasteur on
undisclosed bacterial vaccine towards product development »
Pre-clinical evaluation of IC31® with Wyeth in multiple infectious
vaccine indications progressing well » Revenues and revenue
recognition from technology partnerships in the fourth quarter 2008
expected to clearly exceed EUR 10 m

Vienna (Austria), December 19, 2008 - Intercell today announced that
the Company has transferred on an exclusive basis its pre-clinical
Group B Streptococcus (GBS) vaccine program to Novartis. At the same
time Intercell has kept and received co-exclusive rights for the
development of therapeutic antibodies against Group B Streptococcus
and has in-licensed additional rights on GBS antibodies from
Novartis. The GBS vaccine program was part of the vaccine portfolio
for which Intercell had granted license options to Novartis under a
strategic partnership closed in 2007. This step will trigger a
recognition of revenue from the upfront option fee received under
this strategic partnership.

Furthermore, the collaboration with Sanofi Pasteur, to discover and
develop a vaccine against an un-disclosed bacterial pathogen, has
been extended in order to define a vaccine candidate for development.

The collaboration with Wyeth to use Intercell's proprietary adjuvant
IC31® in various bacterial vaccine targets, which are in pre-clinical
development, is progressing well. The collaboration runs under a
non-exclusive agreement signed in 2006.

"We are very pleased that all our technology partnerships are
progressing very well," states Gerd Zettlmeissl, Chief Executive
Officer of Intercell. "This demonstrates that our Antigen
Identification Program, our adjuvant IC31® and Intercell's new patch
technology are valuable assets of our Company. Given the richness of
our pipeline we will even extend our portfolio of product development
alliances where we expect new partnerships in the near future," adds
Zettlmeissl.

Intercell expects revenues and revenue recognition from existing
technology partnerships to clearly exceed EUR 10m in the fourth
quarter of 2008.

About Group B Streptococcus

Intercell has identified and validated numerous antigens from Group B
Streptococcus (GBS). The most promising antigens will be refined and
used to prevent diseases in the most susceptible neonates (not yet
born and newborn with a weight of less than 1,000 g). In addition,
antibodies will also be given to neonates who already developed
diseases caused by GBS. The vaccine is currently in pre-clinical
development.

GBS causes infections of diverse kind in neonates (not yet born),
newborns, pregnant women and elderly. An infection can result in lung
inflammation (pneumonia), life-threatening systemic inflammatory
response syndrome (sepsis) and brain and cerebrospinal fever
(meningitis). Newborns are at especially high risk for infections and
acquire the infection from their infected mothers, even though the
mothers may be without symptoms.

About IC31®

Vaccines, based on antigens alone, are not always sufficient to
provide full protection. Adjuvants are needed to educate the immune
system to recognize and eliminate the pathogens efficiently.

IC31® is an adjuvant that induces T-cell and B-cell responses by
using a unique synthetic formulation which combines the
immunostimulating properties of an anti-microbial peptide, KLK, and
an immunostimulatory oligodeoxynucleotide, ODN1a. The two component
solution can be simply mixed with antigens; no conjugation is
required.

Intercell currently uses IC31® in collaborations with a number of
global vaccine companies and biotech companies. These collaborations
include amongst others the development of a tuberculosis vaccine in
Phase I clinical trials, which has been partnered with the Danish
Statens Serum Institut and Sanofi Pasteur.

About Intercell's Antigen Identification Program (AIP®)

The design and development of novel subunit vaccines is highly
dependent on the identification and characterization of the proper
antigens. Through AIP® we successfully have identified and refined a
large number of antigens of numerous bacterial pathogens. The
selected antibodies are derived from infected or healthy exposed
individuals and therefore directly mirror the presence, accessibility
and antigenicity of relevant proteins from the particular
microorganism in its human host. The most promising candidates are
validated. AIP® has successfully been applied to identify a large
number of novel antigens from numerous pathogenic organisms including
S. aureus, S. epidermidis, S. pneumoniae, S. agalactiae, S. pyogenes,
E. faecalis, K. pneumoniae, Borrelia spp., ETEC, Shigella, C. jejuni,
non-typeable H. influenzae and M. catarrhalis. It has resulted in
promising in-house product candidates and generated strategic
partnerships.

About Intercell's vaccine patch technology

Intercell's Vaccine Patch is a new and needle free delivery
technology which can be used to:

» Enhance the effect of injected vaccines: Vaccine Enhancement
Patch (VE Patch) » Develop new vaccines which require transcutaneous
administration because the antigen can not be delivered safely or
efficiently through other routes of administration: Vaccine Patch

The patch technology opens up a new way of vaccine delivery that is
easier to administer, faster to deliver and can result in lower or
fewer doses. The patch can boost cellular immunity to a diverse range
of antigens and stimulates both B-cell and T-cell responses. It
contains the heat labile enterotoxin from E. coli (LT), one of the
most potent stimulators of the immune system. When the patch is
applied on the skin, immune stimulants are delivered at the surface
of the skin to Langerhans cells, a major component of the immune
systems. The Langerhans cells, activated by the presence of these
immune stimulants, take up the vaccine antigen and migrate to the
regional draining lymph nodes. There, presentation to the immune
system occurs, eliciting a robust immune response.

Compared with standard immunization via needles, the patch technology
has significant benefits. It is easily administered, the antigen and
adjuvant are directly delivered to the immune system through the
natural defense pathway, which makes vaccination efficient and
results in less side effects. The patch has shown excellent local
tolerability, it is stable at room temperature and strong immune
stimulants can be used since there is no systemic exposure.

At present, the Vaccine Patch is used in-house for the development of
a novel Travelers' Diarrhea vaccine patch about to enter Phase III
trials and the Vaccine Enhancement Patch in the development of a
pandemic Influenza vaccine patch. In addition, the technology is used
in collaboration with Merck & Co., which uses it to conduct
proof-of-principle pre-clinical studies. Intercell is seeking further
collaborations with leading industry players interested in developing
vaccines where fewer doses are desired, product life-cycle management
is needed or use in immune-compromised patients is required.


end of announcement euro adhoc
--------------------------------------------------------------------------------


ots Originaltext: Intercell AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Intercell AG

Lucia Malfent

Head of Corporate Communications

Tel. +43 1 20620-1303

lmalfent@intercell.com

Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Index: ATX Prime, ATX
Börsen: Wiener Börse AG / official market


Kontaktinformationen:

Leider liegen uns zu diesem Artikel keine separaten Kontaktinformationen gespeichert vor.
Am Ende der Pressemitteilung finden Sie meist die Kontaktdaten des Verfassers.

Neu! Bewerten Sie unsere Artikel in der rechten Navigationsleiste und finden
Sie außerdem den meist aufgerufenen Artikel in dieser Rubrik.

Sie suche nach weiteren Pressenachrichten?
Mehr zu diesem Thema finden Sie auf folgender Übersichtsseite. Desweiteren finden Sie dort auch Nachrichten aus anderen Genres.

http://www.bankkaufmann.com/topics.html

Weitere Informationen erhalten Sie per E-Mail unter der Adresse: info@bankkaufmann.com.

@-symbol Internet Media UG (haftungsbeschränkt)
Schulstr. 18
D-91245 Simmelsdorf

E-Mail: media(at)at-symbol.de

177704

weitere Artikel:
  • euro adhoc: SAF AG / Directors' Dealings Mitteilung über Geschäfte von Führungspersonen nach § 15a WpHG -------------------------------------------------------------------------------- Directors Dealings-Mitteilung übermittelt durch euro adhoc mit dem Ziel einer europaweiten Verbreitung. Für den Inhalt ist der Emittent verantwortlich. -------------------------------------------------------------------------------- 15.12.2008 ausserbörslich (euro adhoc) - Personenbezogene Daten: -------------------------------------------------------------------------------- Mitteilungspflichtige Person: ----------------------------- Name: mehr...

  • euro adhoc: DZ BANK AG / Sonstige Kapitalmarkinformation gemäß § 30e WpHG -------------------------------------------------------------------------------- Sonstige Kapitalmarktinformationen gemäß § 30 e WpHG übermittelt durch euro adhoc mit dem Ziel einer europaweiten Verbreitung. Für den Inhalt ist der Emittent verantwortlich. -------------------------------------------------------------------------------- 19.12.2008 Anleihe: EUR 10.000.000 Inhaber-Teilschuldverschreibungen Multi -Callable von 2008/2018; 2. Aufstockung: von EUR 155.000.000 um EUR 10.000.000 auf EUR 165.000.000 ISIN: DE000DZ1HE02; Emission: mehr...

  • euro adhoc: Heiler Software AG / Veröffentlichung gemäß § 26 WpHG Abs. 1 Satz 1 mit dem Ziel der europaweiten Verbreitung -------------------------------------------------------------------------------- Stimmrechtsmitteilung übermittelt durch euro adhoc mit dem Ziel einer europaweiten Verbreitung. Für den Inhalt ist der Emittent verantwortlich. -------------------------------------------------------------------------------- Angaben zum Mitteilungspflichtigen: ----------------------------------- Name: siehe unten Sitz: siehe unten Staat: siehe unten Angaben zum Emittenten: ----------------------- Name: Heiler Software AG Adresse: Mittlerer Pfad 5, mehr...

  • Börsen-Champions: Top 300 mit kräftigen Verlusten Frankfurt am Main (ots) - PwC-Studie: Börsenwert der 300 größten Unternehmen sinkt zwischen 2006 und 2008 um über 25% / Banken und Finanzdienstleister verlieren deutlich / Ausländische Investoren sorgen für Bewegung Die Finanzkrise hat im "Top 300"-Ranking der größten deutschen börsennotierten Unternehmen tiefe Spuren hinterlassen. Mitte Oktober 2008 lag die Marktkapitalisierung der 300 führenden Aktiengesellschaften nur noch bei rund 824,6 Milliarden Euro und damit um gut 285,25 Mrd. Euro unter dem Börsenwert der "Top 300" mehr...

  • KfW Förderbank: Ausweitung der Programme für Energieeffizientes Bauen und Sanieren ab Januar 2009 Frankfurt (ots) - Neu: Zusätzliche Förderung für energetische Einzelmaßnahmen im Programm "Wohnraum Modernisieren" Zuschüsse für energetische Einzelmaßnahmen im CO2-Gebäudesanierungsprogramm Die KfW Förderbank weitet ihre Programme für Energieeffizienten Bauen und Sanieren ab Januar 2009 aus. Im Rahmen der Öko-Plus-Variante des Programms "Wohnraum Modernisieren" werden ab Januar auch Einzelmaßnahmen wie die Erneuerung der Fenster oder der Einbau eines Brennwertkessels aus Haushaltsmitteln des Bundes mit besonders zinsgünstigen mehr...

Mehr zu dem Thema Finanzen

Der meistgelesene Artikel zu dem Thema:

Century Casinos wurde in Russell 2000 Index aufgenommen

durchschnittliche Punktzahl: 0
Stimmen: 0

Bitte nehmen Sie sich einen Augenblick Zeit, diesen Artikel zu bewerten:

Exzellent
Sehr gut
gut
normal
schlecht